Atriva Therapeutics GmbH

📍 Planegg/Martinsried, Germany🗓 Founded 2015👥 16 employees💰 Last funded Jan 2017
Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 in Tübingen by a team of leading scientists in viral research and seasoned industry experts and is based in Tübingen, Frankfurt, and Martinsried (IZB, near Munich), Germany. Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter (@AtrivaTx).
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2015
Founded
Investor geography1 country
Germany
1
Frequently asked questions
Who invested in Atriva Therapeutics GmbH?
Atriva Therapeutics GmbH has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Atriva Therapeutics GmbH last raise funding?
The most recent investment in Atriva Therapeutics GmbH recorded on gritt.io was in January 2017.
When was Atriva Therapeutics GmbH founded?
Atriva Therapeutics GmbH was founded in 2015.
What industry is Atriva Therapeutics GmbH in?
Atriva Therapeutics GmbH operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Atriva Therapeutics GmbH based?
Atriva Therapeutics GmbH is headquartered in Planegg/Martinsried, Germany.